Top 5 Medical Apps in Kuwait Q4 2023

In Q4 2023, the top 5 medical apps in Kuwait exhibited diverse performance metrics, reflecting their unique market positions and user engagement levels. Here’s a closer look at how each app fared during this period, based on data from Sensor Tower.

AMBOSS Medical Knowledge saw a fluctuating revenue stream throughout the quarter. Weekly revenue peaked at around $290 in the week of October 9 and experienced a low of $158 in multiple weeks. The app's weekly active users showed a gradual decline, starting from 112 in late September and dropping to 85 by the end of December.

Complete Anatomy for iPad demonstrated significant variability in both revenue and downloads. Its weekly revenue reached a high of approximately $369 in early November, while the lowest was about $42 in mid-December. Downloads were highest at 208 in early October, tapering off to 18 in early December. Active users peaked at 338 in early October, eventually stabilizing around 152 by December end.

UpToDate Lexidrug experienced a steady revenue stream, with a notable peak of $235 in late October. Downloads showed a marked decline, starting from 51 in early October and dropping to zero for several weeks, with a slight uptick to 14 at the end of December. Active users fluctuated, reaching a high of 172 in early October and settling at 96 by the quarter's end.

Sanford Guide maintained a relatively stable revenue pattern. Revenue peaked at $157 in late October, with the lowest being $56 in mid-December. However, there were no downloads or active user data available for this app during the quarter.

VisualDx displayed a unique trend with a significant revenue spike to $881 in the final week of December, while the rest of the quarter had much lower figures, often below $50. Download and active user data were not available for this app.

These insights from Sensor Tower provide a comprehensive overview of the performance of top medical apps in Kuwait for Q4 2023. For more detailed analytics and data, visit Sensor Tower.